Loading
Endometrial Cancer / Endometrial Neoplasms · Journal article
Journal of Obstetrics and Gynaecology · July 24, 2026
Early or partial results. Treat as a signal, not a conclusion.
This 53-patient prospective observational study compared sleeve gastrectomy, semaglutide, and a lifestyle program (DEAR) in endometrial cancer patients undergoing fertility-sparing treatment. While surgery achieved greater initial weight loss, the lifestyle program demonstrated superior weight maintenance at 2 years and the highest complete tumor remission rate (85.0%).
Prospective observational study. Patients with endometrial cancer receiving fertility-sparing treatment. Intervention: Sleeve gastrectomy (n=10), semaglutide therapy (n=23), or DEAR programme (n=20). Compared with: Three-way comparison among interventions. n = 53.
At 1 year, sleeve gastrectomy reduced BMI 4.04 kg/m2 more than semaglutide (p < 0.05) and 2.12 kg/m2 more than DEAR (p < 0.05) At 2 years, weight regain was less frequent in DEAR (14.3%) versus semaglutide (55.6%) and sleeve gastrectomy (66.7%) groups (p = 0.037) Complete tumor remission rates were highest in DEAR (85.0%), followed by semaglutide (73.9%) and sleeve gastrectomy (60.0%)
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
For endometrial cancer patients seeking fertility preservation, this early evidence suggests lifestyle interventions may offer comparable or superior medium-term weight control and tumor outcomes compared to surgery or pharmacotherapy. However, the observational design and small sample limit definitive recommendations, and treatment selection should remain individualized.
Small prospective observational study comparing three weight-management approaches in endometrial cancer patients, with no randomization and limited sample size limiting causal inference.
As stated by the source record.
Quoted from the source exactly as published.
For endometrial cancer patients seeking fertility preservation, this early evidence suggests lifestyle interventions may offer comparable or superior medium-term weight control and tumor outcomes compared to surgery or pharmacotherapy. However, the observational design and small sample limit definitive recommendations, and treatment selection should remain individualized.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background. To compare sleeve gastrectomy, semaglutide therapy, and the Diet, Exercise, Accompany and Refresh (DEAR) weight management programme for weight control, metabolic improvement, and oncological outcomes in patients with endometrial cancer receiving fertility-sparing treatment.Methods. In this prospective observational study, 53 patients received sleeve gastrectomy (n = 10), semaglutide therapy (n = 23), or the DEAR programme (n = 20) after multidisciplinary assessment and shared decision-making. Anthropometric and metabolic measures and tumour response were assessed over two years.Results. At 1 year, all groups lost weight; the sleeve gastrectomy group had the largest body mass index reduction compared with the semaglutide group (difference = 4.04 kg/m2, p < 0.05) and the DEAR group (difference = 2.12 kg/m2, p < 0.05). By 2 years, weight regain was less frequent in the DEAR group (14.3%) than in the semaglutide (55.6%) and sleeve gastrectomy (66.7%) groups (p = 0.037). The DEAR group showed more stable metabolic improvements and the highest complete tumour remission rate (85.0%), followed by the semaglutide group (73.9%) and the sleeve gastrectomy group (60.0%).Conclusion. Sleeve gastrectomy produced rapid short-term weight loss, whereas the DEAR programme showed better medium-term weight maintenance, metabolic stability, and tumour response. Integrated lifestyle support may be a useful medium-term strategy for patients seeking fertility preservation.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.